Danaher Corporation (ETR:DAP)
Germany
· Delayed Price · Currency is EUR | Market Cap | 118.87B |
| Revenue (ttm) | 21.99B |
| Net Income (ttm) | 3.48B |
| Shares Out | n/a |
| EPS (ttm) | 4.76 |
| PE Ratio | 34.20 |
| Forward PE | 24.24 |
| Dividend | 1.07 (0.63%) |
| Ex-Dividend Date | Jun 27, 2025 |
| Volume | 610 |
| Average Volume | 514 |
| Open | 170.36 |
| Previous Close | 169.88 |
| Day's Range | 168.12 - 170.36 |
| 52-Week Range | 149.72 - 260.00 |
| Beta | 0.80 |
| RSI | 46.20 |
| Earnings Date | Jul 22, 2025 |
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manuf... [Read more]
Financial Performance
In 2024, Danaher's revenue was $23.88 billion, a decrease of -0.06% compared to the previous year's $23.89 billion. Earnings were $3.90 billion, a decrease of -17.79%.
Financial numbers in USD Financial StatementsNews
3-Stock Lunch: Danaher, Progressive, Alphabet
CNBC's "Power Lunch" team is joined by Mike Bailey, director of research at FBB Capital Partners, to discuss what three stocks he is watching.
Illumina downgraded at Scotiabank on outlook; Danaher, Thermo Fisher upgraded
Meta Platforms To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Evercore ...
Our bottom 5 stocks for the first half of 2025 and why we still own them
This is what it will take to for a turnaround in shares of Salesforce, Apple, Bristol Myers, DuPont and Danaher.
Danaher: Biotech Momentum, Cost Cuts And Valuation Re-Rating Should Drive Upside
Danaher is positioned for a revenue rebound, led by strong bioprocessing demand and resilient recurring sales, despite short-term headwinds in Life Sciences and China. Margin outlook is stable, suppor...
Danaher Appoints Martin Stumpe as Chief Technology and AI Officer
WASHINGTON , June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technol...
Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences
WASHINGTON , June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Greg Milosevich has been appointed by its Boa...
Lightning Round: I am horrified at what is happening at Danaher, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: Applied Digital, AST SpaceMobile, Docusign, Workday, Danaher, and SM Energy.
Danaher: High Capex And Low Debt Despite Trump Legislation
Danaher Schedules Second Quarter 2025 Earnings Conference Call
WASHINGTON , June 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2025 on Tuesday, July 22, 2025 b...
Here's How Much $1000 Invested In Danaher 10 Years Ago Would Be Worth Today
Danaher (NYSE: DHR) has outperformed the market over the past 10 years by 2.59% on an annualized basis producing an average annual return of 13.67%. Currently, Danaher has a market capitalization of ...
Prosperity Partners Completes Acquisition of Danaher Attig & Plante
CHICAGO--(BUSINESS WIRE)--Prosperity Partners (“Prosperity”), a Chicago-headquartered tax and accounting business backed by Unity Partners LP (“Unity Partners”), today announced that it has completed ...
How Do Investors Really Feel About Danaher?
Danaher's (NYSE: DHR) short percent of float has fallen 4.1% since its last report. The company recently reported that it has 7.45 million shares sold short , which is 1.17% of all regular shares tha...
SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement
MARLBOROUGH, Mass. — SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE: DHR), and Evosep Biosystems, a global leader in proteomics solut...
SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #ZenoTOF--At ASMS 2025, SCIEX launches the ZenoTOF 8600 system, setting a new standard in accurate mass quantitation.
Software Launches for SCIEX OS Ecosystem to Help Scientists Accelerate Discoveries and Streamline Lab Operations
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #AI--SCIEX announces three software ecosystem enhancements at ASMS, supporting the theme that “all science is data science now.”.
SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #Evocep--SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement.
Danaher in partnership with AstraZeneca for diagnostic tests for precision medicine
Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine
Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnostics This partnership aims to create a framework for rapid...
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI
Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...
$100 Invested In Danaher 10 Years Ago Would Be Worth This Much Today
Danaher (NYSE: DHR) has outperformed the market over the past 10 years by 1.68% on an annualized basis producing an average annual return of 12.54%. Currently, Danaher has a market capitalization of ...
Market Whales and Their Recent Bets on DHR Options
High-rolling investors have positioned themselves bearish on Danaher (NYSE: DHR), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tra...
P/E Ratio Insights for Danaher
Looking into the current session, Danaher Inc. (NYSE: DHR) shares are trading at $197.77, after a 0.69% spike. Moreover, over the past month, the stock increased by 2.97% , but in the past year, decr...
Third Point adds US Steel, Kenvue, exits Danaher, Tesla among Q1 moves
Discover Third Point's latest investment moves in Q1: new stakes in US Steel & Nvidia, exits from Tesla & Danaher, and shifts across tech & industrial giants.
Danaher Corporation (DHR) BofA Securities 2025 Healthcare Conference (Transcript)
Danaher Corporation (NYSE:DHR) BofA Securities 2025 Healthcare Conference May 15, 2025 1:00 PM ETCompany ParticipantsRainer Blair - CEOConference Call...